



(51) International Patent Classification:

A61K 35/17 (2015.01) A61P 35/00 (2006.01)
C07K 14/74 (2006.01)

(21) International Application Number:

PCT/US2021/046751

(22) International Filing Date:

19 August 2021 (19.08.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/068,245 20 August 2020 (20.08.2020) US
63/085,971 30 September 2020 (30.09.2020) US

(71) Applicant: **A2 BIOTHERAPEUTICS, INC.** [US/US];
30301 Agoura Road, Suite 210, Agoura Hills, CA 91301 (US).

(72) Inventors: **KAMB, Carl, Alexander**; c/o A2 Biotherapeutics, Inc., 30301 Agoura Road, Suite 210, Agoura Hills, CA 91301 (US). **WARSHAVIAK, Dora, Toledo**; c/o A2 Biotherapeutics, Inc., 30301 Agoura Road, Suite 210, Agoura Hills, CA 91301 (US). **TOKATLIAN, Talar**; c/o A2 Biotherapeutics, Inc., 30301 Agoura Road, Suite 210, Agoura Hills, CA 91301 (US). **HAMBURGER, Agnes**; c/o A2 Biotherapeutics, Inc., 30301 Agoura Road, Suite 210, Agoura Hills, CA 91301 (US).

(74) Agent: **CHRISTIANSEN, William, T.** et al.; Cooley LLP,
1299 Pennsylvania Ave., Suite 700, Washington, DC 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

(54) Title: COMPOSITIONS AND METHODS FOR TREATING MESOTHELIN POSITIVE CANCERS

FIG. 15B



(57) Abstract: The disclosure provides immune cells comprising a first activator receptor specific to mesothelin and a second inhibitory receptor specific to a ligand that has been lost in a mesothelin-positive cancer cell, and methods of making and using same for the treatment of cancer.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*